EBS
Emergent Biosolutions Inc
6.70$
-1.3%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -46.5% | -295.0% | – | +223.6% | -152.0% | – | – | -102.2% | – | -143.5% | – | – | |
| – | +5.7% | -5.7% | +2.2% | -7.4% | -1.5% | -2.3% | -7.5% | -0.4% | +0.4% | +0.0% | +2.1% | – | |
| – | +0.0% | +47.5% | -6.8% | -58.2% | +87.0% | -65.1% | +206.7% | +4.3% | +10.4% | -64.2% | +263.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -29.3% | -309.7% | – | -68.1% | -230.0% | – | – | -185.1% | – | -163.2% | – | – | |
| – | -9.5% | -5.3% | -57.4% | +26.1% | -70.7% | +111.8% | -19.4% | +17.2% | +14.7% | -38.5% | -12.5% | – | |
| – | -39.7% | -5.3% | -57.4% | – | -74.5% | +108.0% | -71.1% | -119.8% | +14.7% | -38.5% | +2,079.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +300.0% | -50.0% | – | +3,933.3% | -99.6% | -7,000.0% | +29.0% | +2.2% | -1.1% | +0.0% | – | |
| – | – | – | – | – | -100.0% | – | – | – | +1,375.4% | – | – | – | |
| – | – | +766.0% | -225.1% | +254.2% | – | -180.0% | +1,500.0% | +148.4% | +616.4% | -90.0% | +114.0% | – | |
| – | – | -236.8% | – | – | -159.5% | – | +150.4% | -118.4% | – | – | – | – | |
| – | -56.3% | -454.6% | – | +244.8% | -155.2% | – | – | -105.5% | – | -149.1% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.